Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Arena

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal CancerLuca Lazzari, Giorgio Corti, Gabriele Picco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal CancerFrancisco J Sánchez-Martín, Beatriz Bellosillo, Mariona Gelabert-Baldrich, et al.
Nature Communications|December 9, 2016
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancerBeth O Van Emburgh, Sabrina Arena, Giulia Siravegna, et al.
Journal of Translational Medicine|November 23, 2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancerAntonio Agostini, Ilaria Guerriero, Geny Piro, et al.
Cell Reports. Medicine|January 16, 2024
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cellsAlberto Sogari, Emanuele Rovera, Gaia Grasso, et al.
Science (New York, N.Y.)|November 9, 2019
Adaptive mutability of colorectal cancers in response to targeted therapiesMariangela Russo, Giovanni Crisafulli, Alberto Sogari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2022
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerErika Durinikova, Nicole M Reilly, Kristi Buzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2015
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal CancerSabrina Arena, Beatriz Bellosillo, Giulia Siravegna, et al.
Cancer Discovery|April 28, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 MutationsMichelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego, et al.
Cancer Discovery|April 10, 2021
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and ImmunotherapyGabriele Picco, Chiara M Cattaneo, Esmée J van Vliet, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal CancerLuca Lazzari, Giorgio Corti, Gabriele Picco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal CancerFrancisco J Sánchez-Martín, Beatriz Bellosillo, Mariona Gelabert-Baldrich, et al.
Nature Communications|December 9, 2016
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancerBeth O Van Emburgh, Sabrina Arena, Giulia Siravegna, et al.
Journal of Translational Medicine|November 23, 2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancerAntonio Agostini, Ilaria Guerriero, Geny Piro, et al.
Cell Reports. Medicine|January 16, 2024
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cellsAlberto Sogari, Emanuele Rovera, Gaia Grasso, et al.
Science (New York, N.Y.)|November 9, 2019
Adaptive mutability of colorectal cancers in response to targeted therapiesMariangela Russo, Giovanni Crisafulli, Alberto Sogari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2022
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerErika Durinikova, Nicole M Reilly, Kristi Buzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2015
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal CancerSabrina Arena, Beatriz Bellosillo, Giulia Siravegna, et al.
Cancer Discovery|April 28, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 MutationsMichelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego, et al.
Cancer Discovery|April 10, 2021
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and ImmunotherapyGabriele Picco, Chiara M Cattaneo, Esmée J van Vliet, et al.
Pageof 6